These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33769456)

  • 1. Laboratory and Clinical Implications of Incidental and Secondary Germline Findings During Tumor Testing.
    Cushman-Vokoun A; Lauring J; Pfeifer J; Olson DR; Berry A; Thorson J; Voelkerding K; Myles J; Barbeau J; Chandra P; Li M; Vance GH; Jensen BW; Hansen MY; Yohe S
    Arch Pathol Lab Med; 2022 Jan; 146(1):70-77. PubMed ID: 33769456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reporting incidental findings in genomic scale clinical sequencing--a clinical laboratory perspective: a report of the Association for Molecular Pathology.
    Hegde M; Bale S; Bayrak-Toydemir P; Gibson J; Jeng LJ; Joseph L; Laser J; Lubin IM; Miller CE; Ross LF; Rothberg PG; Tanner AK; Vitazka P; Mao R
    J Mol Diagn; 2015 Mar; 17(2):107-17. PubMed ID: 25684271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Window Into Clinical Next-Generation Sequencing-Based Oncology Testing Practices.
    Nagarajan R; Bartley AN; Bridge JA; Jennings LJ; Kamel-Reid S; Kim A; Lazar AJ; Lindeman NI; Moncur J; Rai AJ; Routbort MJ; Vasalos P; Merker JD
    Arch Pathol Lab Med; 2017 Dec; 141(12):1679-1685. PubMed ID: 29028368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.
    Li MM; Datto M; Duncavage EJ; Kulkarni S; Lindeman NI; Roy S; Tsimberidou AM; Vnencak-Jones CL; Wolff DJ; Younes A; Nikiforova MN
    J Mol Diagn; 2017 Jan; 19(1):4-23. PubMed ID: 27993330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.
    Meric-Bernstam F; Brusco L; Daniels M; Wathoo C; Bailey AM; Strong L; Shaw K; Lu K; Qi Y; Zhao H; Lara-Guerra H; Litton J; Arun B; Eterovic AK; Aytac U; Routbort M; Subbiah V; Janku F; Davies MA; Kopetz S; Mendelsohn J; Mills GB; Chen K
    Ann Oncol; 2016 May; 27(5):795-800. PubMed ID: 26787237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-Generation Sequencing Somatic and Germline Assay Troubleshooting Guide Derived From Proficiency Testing Data.
    Nardi V; Tsuchiya KD; Kim AS; Bean LJH; Halley JG; Long TA; Szelinger S; Vasalos P; Thorson JA; Moyer AM; Moncur JT
    Arch Pathol Lab Med; 2022 Apr; 146(4):451-461. PubMed ID: 34424952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance Comparison of Different Analytic Methods in Proficiency Testing for Mutations in the
    Moncur JT; Bartley AN; Bridge JA; Kamel-Reid S; Lazar AJ; Lindeman NI; Long TA; Merker JD; Rai AJ; Rimm DL; Rothberg PG; Vasalos P; Kim AS
    Arch Pathol Lab Med; 2019 Oct; 143(10):1203-1211. PubMed ID: 30969158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Return of non-ACMG recommended incidental genetic findings to pediatric patients: considerations and opportunities from experiences in genomic sequencing.
    Bowling KM; Thompson ML; Kelly MA; Scollon S; Slavotinek AM; Powell BC; Kirmse BM; Hendon LG; Brothers KB; Korf BR; Cooper GM; Greally JM; Hurst ACE
    Genome Med; 2022 Nov; 14(1):131. PubMed ID: 36414972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Validation of Clinical Whole-Exome and Whole-Genome Sequencing for Detection of Germline Variants in Inherited Disease.
    Hegde M; Santani A; Mao R; Ferreira-Gonzalez A; Weck KE; Voelkerding KV
    Arch Pathol Lab Med; 2017 Jun; 141(6):798-805. PubMed ID: 28362156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.
    Jennings LJ; Arcila ME; Corless C; Kamel-Reid S; Lubin IM; Pfeifer J; Temple-Smolkin RL; Voelkerding KV; Nikiforova MN
    J Mol Diagn; 2017 May; 19(3):341-365. PubMed ID: 28341590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding variations in secondary findings reporting practices across U.S. genome sequencing laboratories.
    Ackerman SL; Koenig BA
    AJOB Empir Bioeth; 2018; 9(1):48-57. PubMed ID: 29131714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrating next-generation sequencing into pediatric oncology practice: An assessment of physician confidence and understanding of clinical genomics.
    Johnson LM; Valdez JM; Quinn EA; Sykes AD; McGee RB; Nuccio R; Hines-Dowell SJ; Baker JN; Kesserwan C; Nichols KE; Mandrell BN
    Cancer; 2017 Jun; 123(12):2352-2359. PubMed ID: 28192596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory compliance with the American Society of Clinical Oncology/college of American Pathologists guidelines for human epidermal growth factor receptor 2 testing: a College of American Pathologists survey of 757 laboratories.
    Nakhleh RE; Grimm EE; Idowu MO; Souers RJ; Fitzgibbons PL
    Arch Pathol Lab Med; 2010 May; 134(5):728-34. PubMed ID: 20441503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Traditional roles in a non-traditional setting: genetic counseling in precision oncology.
    Everett JN; Gustafson SL; Raymond VM
    J Genet Couns; 2014 Aug; 23(4):655-60. PubMed ID: 24578120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary findings: How did we get here, and where are we going?
    Ormond KE; O'Daniel JM; Kalia SS
    J Genet Couns; 2019 Apr; 28(2):326-333. PubMed ID: 30821867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reporting practices for unsolicited and secondary findings from next-generation sequencing technologies: Perspectives of laboratory personnel.
    Vears DF; Sénécal K; Borry P
    Hum Mutat; 2017 Aug; 38(8):905-911. PubMed ID: 28512758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor genome analysis includes germline genome: are we ready for surprises?
    Catenacci DV; Amico AL; Nielsen SM; Geynisman DM; Rambo B; Carey GB; Gulden C; Fackenthal J; Marsh RD; Kindler HL; Olopade OI
    Int J Cancer; 2015 Apr; 136(7):1559-67. PubMed ID: 25123297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A framework for reporting secondary and incidental findings in prenatal sequencing: When and for whom?
    Vears D; Amor DJ
    Prenat Diagn; 2022 May; 42(6):697-704. PubMed ID: 35032068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer susceptibility syndromes in children in the area of broad clinical use of massive parallel sequencing.
    Kuhlen M; Borkhardt A
    Eur J Pediatr; 2015 Aug; 174(8):987-97. PubMed ID: 25982339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.